Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Durect
Biotech
Bausch Health bags phase 3-ready liver prospect in $63M buyout
Bausch Health has struck a deal to buy Durect, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential.
Nick Paul Taylor
Jul 29, 2025 9:35am
Durect fails alcohol-associated hepatitis trial, plans phase 3
Nov 8, 2023 7:57am
Catalent shakes up leadership, taps new CEO—Chutes & Ladders
Jul 8, 2022 9:30am
Durect's painkiller gets evenly split decision from expert panel
Jan 17, 2020 8:30am
Durect shares rocked by midstage psoriasis flop
Jan 3, 2020 8:00am
AASLD: Durect's alcoholic hepatitis med shows early promise
Nov 12, 2019 8:45am
